Hepatitis B Treatment Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Date : Mar 2018

Formats :
Report Code : PMR83649615

Category : Pharmaceutical and Healthcare
No Of Pages :
Hepatitis B Treatment Market
HepatitisB is also known serum hepatitis which is an infectious disease of the liver caused by HepatitisB virus HBV. Hepatitis B is classified into two types namely, acute and chronic. In this condition, the virus interferes with the hepatocytes and the liver became inflamed. HepatitisB is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. HepatitisB virus is unable to cross the skin or mucous membrane. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome AIDS, and people treated with immunosuppressant drugs and haemodialysis patients are easily develop an infection with HepatitisB Virus. The symptoms of the Hepatitis B do not develop until after a few weeks of exposure. The severity in Hepatitis may cause the cirrhosis, liver failure, and hepatocellular carcinoma HCC. A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.

The global Hepatitis B treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization WHO, chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global hepatitis B treatment market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global hepatitis B treatment market over the forecast period.

Hepatitis B treatment market segmented on the basis of drug class, route 0f administration, and distribution channel

Based on drug class, hepatitis B treatment market has been segmented into the following:
Chemo Therapy
Immunosuppressant Therapy
Nucleoside Analogue

Based on route of administration, hepatitis B treatment market has been segmented into the following:
Oral
Parenteral
Others

Based on distribution channel, hepatitis B treatment market has been segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others

Geographically, hepatitis B treatment market is in growing stage, as various government organizations are initiating awareness programs to prevent the hepatitis B infection. Increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of hepatitis B virus in which approximately 15–25% of carriers will develop cirrhosis, hepatocellular carcinoma HCC, or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio’s highlyoptimized, multiantigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies are announced that Benitec has acquired the full rights to the preclinical ddRNAibased hepatitis B HBV therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, in October 2010, U.S. Food and Drug Administration approved the Baraclude Entecavir for hepatitis B treatment with the decompensated liver disease in adults manufactured by Bristol Myers Squibb. Moreover, various drugs for the hepatitis B treatment in the pipeline also expected to propel the hepatitis B treatment market over the forecast period.

Geographically, the hepatitis B treatment market has been segmented into following regions Viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America is expected to hold a dominant share in hepatitis B market owing to increase In the prevalence of hepatitis B infection according to Centres for Disease Prevention and Control CDC, approximately 1.4 Million patients in the United States are chronically infected with hepatitis B Virus, rise in the awareness towards the use of noveltechnologies and products for hepatitis B treatment, and increase in the research and development activities are the key factors bolster the hepatitis B treatment market in North America region. Europe holds a key share in hepatitis B treatment market owing to increase in the prevalence of hepatitis B infection in Russia, the prevalence rate is approximately 3712 cases per 100,000 people, rise in the geriatric population, change in the lifestyle, and increase in the research and development activities might boost the hepatitis B treatment market in Europe region. Asian Pacific is a key region for hepatitis b treatment market attributed to increase in the prevalence of hepatitis B infection in China, there are 7420 prevalent cases per 100,000 people, rise in the population in Asia Pacific region, and increase in the healthcare infrastructure and healthcare expenditure. Middle East & Africa region expected to exhibit significant growth due to highest prevalence of global hepatitis B infection which is approximately 10,000 prevalent cases per 100,000 people.

Some of the players in hepatitis B treatment market are F. Hoffmann La Roche Ltd. Switzerland, GlaxoSmithKline, plc. U.K., BristolMyers Squibb U.S, Novartis AG Switzerland, Merck and Co U.S, Novira Therapeutics Inc. U.S., Johnson & Johnson U.S., Inovio Pharmaceuticals Inc. U.S., Benitec biopharma Ltd. Australia, Gilead Sciences U.S., Cipla Inc. India, and Biomics biotechnologies China to name a few.

In January 2018, Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy tenofovir alafenamide, TAF for the treatment of chronic hepatitis B virus HBV infection in adults and adolescents aged 12 years and older with body weight at least 35 kg

In December 2017, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection
1. Executive Summary
2. Global Hepatitis B Treatment Market Introduction
2.1. Global Hepatitis B Treatment Market – Taxonomy
2.2. Global Hepatitis B Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Hepatitis B Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hepatitis B Treatment Market Dynamic Factors Impact Analysis
4. Global Hepatitis B Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Opportunity Analysis
5. Global Hepatitis B Treatment Market, By Drug Class, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1. Chemo Therapy
5.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Immunosuppressant Therapy
5.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
6. Global Hepatitis B Treatment Market, By Route of Administration, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1. Oral
6.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
7. Global Hepatitis B Treatment Market, By Distribution Channel, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Hepatitis B Treatment Market Forecast, By Region, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1. North America
8.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. AsiaPacific
8.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
9. North America Hepatitis B Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
9.1. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Chemo Therapy
9.1.2. Immunosuppressant Therapy
9.1.3. Nucleoside Analogue
9.2. Route of Administration Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.2.1. Oral
9.2.2. Pareneteal
9.2.3. Others
9.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.3.1. Hospital Pharmacies
9.3.2. Retail pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
9.4.1. U.S.
9.4.2. Canada
9.5. North America Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
9.6. North America Hepatitis B Treatment Market Dynamics – Trends
10. Europe Hepatitis B Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
10.1. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Chemo Therapy
10.1.2. Immunosuppressant Therapy
10.1.3. Nucleoside Analogue
10.2. Route of Administration Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.2.1. Oral
10.2.2. Pareneteal
10.2.3. Others
10.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.3.1. Hospital Pharmacies
10.3.2. Retail pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
10.6. Europe Hepatitis B Treatment Market Dynamics – Trends
11. AsiaPacific Hepatitis B Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
11.1. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Chemo Therapy
11.1.2. Immunosuppressant Therapy
11.1.3. Nucleoside Analogue
11.2. Route of Administration Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.2.1. Oral
11.2.2. Pareneteal
11.2.3. Others
11.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.3.1. Hospital Pharmacies
11.3.2. Retail pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of AsiaPacific
11.5. AsiaPacific Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
11.6. AsiaPacific Hepatitis B Treatment Market Dynamics – Trends
12. Latin America Hepatitis B Treatment Market Analysis, 2013 2013 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
12.1. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Chemo Therapy
12.1.2. Immunosuppressant Therapy
12.1.3. Nucleoside Analogue
12.2. Route of Administration Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.2.1. Oral
12.2.2. Pareneteal
12.2.3. Others
12.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.3.1. Hospital Pharmacies
12.3.2. Retail pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Hepatitis B Treatment Market Dynamics – Trends
13. Middle East and Africa Hepatitis B Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
13.1. Drug Class Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.1.1. Chemo Therapy
13.1.2. Immunosuppressant Therapy
13.1.3. Nucleoside Analogue
13.2. Route of Administration Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.2.1. Oral
13.2.2. Pareneteal
13.2.3. Others
13.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.3.1. Hospital Pharmacies
13.3.2. Retail pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
13.4.1. Gulf Cooperation Council GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Hepatitis B Treatment Market Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
13.6. MEA Hepatitis B Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. F. Hoffmann La Roche Ltd. Switzerland
14.2.2. GlaxoSmithKline, plc. U.K.
14.2.3. BristolMyers Squibb U.S
14.2.4. Novartis AG Switzerland
14.2.5. Merck and Co Inc., U.S
14.2.6. Novira Therapeutics Inc. U.S.
14.2.7. Johnson & Johnson Services Inc., U.S.
14.2.8. Inovio Pharmaceuticals Inc. U.S.
14.2.9. Benitec biopharma Ltd. Australia
14.2.10. Gilead Sciences U.S.
14.2.11. Cipla Inc. India
14.2.12. Biomics biotechnologies China
15. Research Methodology
16. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to choose PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....

About Report

Planet Market Reports added Latest and detailed market study report that focuses on “Hepatitis B Treatment Market" Which offers essential information based on fresh ideas into Hepatitis B Treatment Market industry along with unique market analysis which covers current top Manufactures in Hepatitis B Treatment Market, growth, Consumption Demand, challenges, Historical data, subjects wise Survey of each chapters, Regional Insights, and Advancing industry trends, which will help our clients to aim Hepatitis B Treatment Market. In addition, the report helps the customers to get a brief idea about Future demand and specifications of products which ensures the driving long-term income and productivity of global market.